Cargando…
Preserved C-reactive protein responses to blood stream infections following tocilizumab treatment for COVID-19
Autores principales: | Wey, Emmanuel Q., Bristow, Clare, Nandani, Aarti, O'Farrell, Bryan, Pang, Jay, Lanzman, Marisa, Yang, Shuang, Ho, Soo, Mack, Damien, Spiro, Michael, Balakrishnan, Indran, Bhagani, Sanjay, Pollara, Gabriele |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The British Infection Association. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363426/ https://www.ncbi.nlm.nih.gov/pubmed/34400218 http://dx.doi.org/10.1016/j.jinf.2021.08.017 |
Ejemplares similares
-
β-lactam allergy: clinical implications and costs
por: Satta, Giovanni, et al.
Publicado: (2013) -
P09 Activity of newer antibiotics against NDM- and OXA-48-producing organisms
por: Mohamed, Hodman, et al.
Publicado: (2022) -
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
por: Rosas, Ivan O., et al.
Publicado: (2021) -
Tocilizumab: Blood stream infection of methicillin-susceptible Staphylococcus aureus and off label use: case report
Publicado: (2021) -
Privacy-preserving aggregation of personal health data streams
por: Kim, Jong Wook, et al.
Publicado: (2018)